ZEUS anti-inflammatory trial misses, but cardiologists keep pursuing inflammation

· Health

Findings from the ZEUS phase 3 clinical trial, led by Mass General Brigham researcher Paul Ridker, indicate that targeting inflammation in cardiovascular disease may be less straightforward than hoped. The trial is described as neutral in its results, and the drug involved is identified in coverage as a Novo Nordisk therapy; the negative outcome has prompted commentary on how much faith to place in new technologies touted as speeding drug research. Despite the miss, cardiologists told STAT they will still pursue anti-inflammatory approaches, arguing that negative results do not invalidate the role of inflammation in cardiovascular disease. Inflammation, like cholesterol, is considered a causal contributor to cardiovascular risk, making the field's next steps a focus for drugmakers and clinicians.

Why it matters：The trial's neutral result tests whether anti-inflammatory cardiovascular drugs can become a mainstream class, a question that shapes pipelines at multiple large drugmakers.

Key points

  • ZEUS was a global phase 3 trial led by Paul Ridker of Mass General Brigham.
  • The drug is identified as a Novo Nordisk therapy.
  • Cardiologists say negative results do not invalidate inflammation's role.

Sources (original reporting)

More stories from this day